Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase


Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and imatinib-intolerant patients with chronic myelogenous leukemia (CML) have been established. Here, an open-label phase II study evaluated the efficacy and safety of dasatinib in 50 Japanese patients with imatinib-resistant or imatinib-intolerant CML during the chronic phase (CML-CP). Dasatinib was effective in imatinib-resistant and imatinib-intolerant patients. After 12 months of dasatinib therapy, 35 patients (70%) had achieved a major molecular response (MMR) and 16 patients (32%) had achieved a complete molecular response (CMR). Among the imatinib-resistant CML-CP cohort, 21 and 8 patients had achieved an MMR and a CMR after 12 months of dasatinib therapy, respectively. Among the imatinib-intolerant CML-CP cohort, 14 and 8 patients had achieved an MMR and a CMR after 12 months of dasatinib therapy, respectively. After 18 months of dasatinib therapy, 38 out of 50 patients (76.0%) had achieved an MMR and 19 patients (38.0%) had achieved a CMR. A lower level of BCR-ABL transcript at 1 or 3 months after the initiation of dasatinib treatment was more strongly correlated with the BCR-ABL transcript level at 12 and 18 months ($p < 0.001$) than a higher level of BCR-ABL. The T315I mutation was identified in two patients receiving dasatinib therapy. Dasatinib was generally well tolerated, with only 3 patients (5%) having treatment discontinuation as a result of adverse hematologic events (thrombocytopenia, anemia, neutropenia) and/or non-hematologic events at a 12-month follow-up evaluation. Dasatinib was a safe and effective treatment for Japanese patients with imatinib-resistant or imatinib-intolerant CML. In addition, the molecular response at 1 or 3 months predicted a response to dasatinib at 12 or 18 months. [J Clin Exp Hematop 54(3) : 197-204, 2014]
Keywords: CML, dasatinib, imatinib-resistant, imatinib-intolerant, BCR/ABL

INTRODUCTION

Chronic myeloid leukemia (CML) is caused by abnormalities in hematopoietic stem cells resulting in the uncontrolled proliferation of cells originating from the bone marrow. The BCR-ABL fusion protein produced by the Philadelphia chromosome (Ph) is a major molecular cause of CML.1

Imatinib is a selective BCR-ABL inhibitor that is effective against CML.2-4 However, resistance to imatinib gradually develops in many patients with CML who are treated with imatinib, and 31% of these patients discontinue imatinib treatment within 5 years because of insufficient responses or unacceptable toxicity.5 As major factors responsible for the development of resistance to imatinib, numerous point mutations in BCR-ABL have been reported.6-8 Additional factors including BCR-ABL gene amplification,6,9 excretion of the drug through a P-glycoprotein efflux pump,10,11 and the activation of a signal transduction pathway for SRC family kinase and other signals12,13 have also been implicated in the development of resistance. In this regard, the development of new treatments is needed for patients with insufficient responses to imatinib and in whom imatinib cannot be continued at an effective dose because of toxicity.

Dasatinib (BMS-354825) is an oral tyrosine kinase inhibitor that exerts inhibitory activity against BCR-ABL and SRC family kinase. It binds in vitro to both active and inactive BCR-ABL and is 325 times more potent than imatinib and 16 times more potent than nilotinib against wild-type BCR-ABL-expressing cells.14 Five phase 2 studies, collectively known as START (SRC/ABL Tyrosine kinase inhibition Activity Research Trials of dasatinib), have demonstrated that dasatinib is safe and can elicit a hematologic and cytogenetic response in patients with imatinib-resistant or imatinib-intolerant CML or Ph-positive acute lymphocytic leukemia.15-18 Dasatinib was shown to be highly effective, with 91% of patients in the chronic phase of CML (CML-CP) exhibiting a complete hematologic response and 62% exhibiting a major cytogenetic response. The efficacy of dasatinib for CML-CP was durable, and the rate of a major cytogenetic response was 88%; the progression-free survival rate was 80% and the overall survival rate was 94% at a 2-year follow-up.19 However, clinical data for second-line dasatinib therapy are lacking for imatinib-resistant and imatinib-intolerant CML-CP in Japan.

In the present study, we conducted an open-label phase 2 study of dasatinib in Japanese patients with imatinib-resistant or imatinib-intolerant CML-CP. To determine the molecular responses to dasatinib, BCR-ABL transcripts in the peripheral blood were evaluated using quantitative reverse transcriptase-polymerase chain reaction (Q-RT-PCR) at baseline and every month during the study; the results were then compared with the levels of total ABL transcripts.

PATIENTS AND METHODS

Patients and treatment

This study was a phase II analysis of a clinical trial conducted by the Kanto CML Study Group (registered at http://clinicaltrials.gov as NCT00866736). The study was conducted in accordance with the Declaration of Helsinki. The protocol was reviewed and approved by a recognized ethics review committee in each institution that participated in this study. Informed consent was obtained from all patients before entry into this study.

Japanese patients with CML-CP who were resistant or intolerant to first-line imatinib therapy participated in a prospective phase II study in order to evaluate the efficacy and safety of second-line dasatinib therapy. Patients who were at least 15 years of age were eligible for entry if they had imatinib-resistant or imatinib-intolerant CML-CP. The chronic phase of CML was defined as less than 15% blasts in the peripheral blood and bone marrow, less than 20% basophils in the peripheral blood, less than 30% blasts plus promyelocytes in the peripheral blood and bone marrow, a platelet count of at least 100 × 10^9/L unless thrombocytopenia was caused by recent therapy, and no extramedullary involvement other than in the liver or spleen. Patients with prior accelerated-phase or blast crisis CML were not eligible for inclusion in the trial.

Imatinib resistance was defined as the lack of a partial cytogenetic response after 3 months of imatinib treatment, the lack of a complete cytogenetic response (CCyR, 0.1-1.0% of BCR-ABL/ABL) after 6 months of treatment, or the lack of a major molecular response (MMR, less than 0.1% of BCR-ABL/ABL) after 12 months of treatment. Imatinib intolerance was defined as a non-hematologic toxicity of at least grade 2 or a hematologic toxicity of grade 3 or 4 persisting for more than 7 days in response to treatment with imatinib at a dose of 400 mg or more.

Patients with BCR-ABL mutations, which are associated with dasatinib resistance,14 were excluded from the analysis. None of the patients exhibited neutropenia (< 1,000/µL) at the start of dasatinib treatment.

The real-time quantitative reverse transcription-polymerase chain reaction (RQ-PCR) analysis was performed by Bio Medical Laboratories (BML, Inc., Tokyo, Japan). Thus, the level of BCR-ABL transcripts is shown using conversion factor (CF).20 Specifically, the level of measured BCR-ABL transcripts was multiplied by CF and the level of international-scale BCR-ABL transcripts is shown in this manuscript.20,21 A complete molecular response (CMR) was
defined as a peripheral \( BCR-ABL/ABL \) transcript ratio below the detection limit of the RQ-PCR analysis widely used throughout Japan, that is, a peripheral \( BCR-ABL/ABL \) ratio < \( 10^{-4.16} \) (0.0069%) on the international scale (IS). MMR was defined as 0.1% of \( BCR-ABL/ABL \).

**Treatment with dasatinib**

Patients received an oral dose of 100 mg of dasatinib once daily. Therapy could be interrupted or reduced to 70 mg daily or 50 mg daily in response to a hematologic toxicity of at least grade 3 or a non-hematologic toxicity of at least grade 2. When therapy was interrupted, the treatment was then reinitiated at a reduced dose level or discontinued altogether, depending on the severity of the adverse event and on the number of times the same event had occurred. In addition, the investigator and the sponsor made all dose reduction or discontinuation decisions for patients with any signs of bleeding or hemorrhage of any grade. Follow-up for 18 months has been performed in all cases.

**Patient evaluations**

The cytogenetic and hematologic responses to dasatinib were monitored using peripheral blood samples. Complete blood counts were analyzed once weekly for the first 12 weeks and every 3 months thereafter. The assessment of drug toxicities was continuous and included a physical examination to monitor adverse events that was conducted weekly for the first month and every 4 weeks thereafter. mRNA was collected from the peripheral blood samples and was analyzed for \( BCR-ABL \) gene point mutations using denaturing high-performance liquid chromatography and sequencing; the level of expression was examined using RQ-PCR. To determine the molecular responses to dasatinib, the \( BCR-ABL \) transcripts in peripheral blood were evaluated using Q-RT-PCR at baseline, one month, and every three months during the study, and the results were compared with the levels of total \( ABL \) transcripts. Cytogenetic responses were based on the prevalence of Ph-positive interphase among at least 100 leukocytes in each peripheral blood sample. We used fluorescence in situ hybridization with BCR and ABL double-color probes to detect Ph-positive leukocytes. The criteria for cytogenetic responses according to the percentage of Ph-positive cells in interphase among the peripheral leukocytes were as follows: CCyR, 0%; a partial cytogenetic response, 1% to 35%; minor cytogenetic response, 36% to 65%; minimal cytogenetic response, 66% to 95%; and no cytogenetic response, 96% to 100%.

**Statistical analysis**

The primary endpoint was MMR rate in CML patients at 12 months. Secondary endpoints were safety after treatment with dasatinib, CMR rate, and efficacy for patients with \( BCR-ABL \) point mutations. On the basis of previous evidence, we...
set our goal at an MMR rate of 35%. In this situation, the required sample size was 55 patients to detect a difference between a threshold MMR rate of 15% and a target MMR rate using exact test for single proportion with one-sided alpha error of 2.5% and statistical power of 90%. To account for dropouts, the number of patients to be accrued was set at 60 in total.

The observed MMR rate at 12 months was compared with 15% using binomial test in the primary analysis. We also calculated the exact 95% confidence intervals (CI) for each proportion. The MMR rate and the CMR rate were estimated at each follow-up time. The associations between molecular response at 1 month or 3 months and the response at 12 months were evaluated using a chi-squared test. All analyses were performed using SAS version 9.3.

**RESULTS**

Sixty-five patients were enrolled between March 2009 and March 2010. Four of these 65 patients were determined to be ineligible for inclusion in the study, so they were excluded (Fig. 1). Three patients with imatinib-intolerant CML-CP ultimately did not receive dasatinib, so these patients were also excluded from the present analysis. Since eight of the registered patients had attained an MMR at the time of registration, these eight patients were additionally excluded.20 The remaining 50 patients were analyzed statistically. Table 1 shows the characteristics of the patients. The results presented are for the final cohort of 50 patients: 31 with imatinib-resistant CML-CP and 19 with imatinib-intolerant CML-CP.

The patient demographics and baseline disease characteristics are representative of the patient population with imatinib-resistant or imatinib-intolerant CML-CP (Table 1).

### Dosage of dasatinib

All the patients received an oral dose of 100 mg of dasatinib once daily at baseline. When a hematologic toxicity of at least grade 3 or a non-hematologic toxicity of at least grade 2 was observed, the dosage of dasatinib was reduced or transiently interrupted. Thus, dasatinib was continued at 100 mg/day for 12 months in 20 (40%) of the 50 patients. The dose intensity at 12 months was 82.0 mg/day. Six patients discontinued dasatinib treatment after 12 months. There were no patients who died in 12 months.

### Molecular response

After 12 months of dasatinib therapy, 35 patients (70%; 95% CI = 55.4%-82.1%) had achieved an MMR and 16 patients (32%; 95% CI = 19.5%-46.7%) had achieved a CMR. Among the imatinib-resistant CML-CP cohort, 21 and 8 patients achieved an MMR and a CMR, respectively. The observed MMR rate showed a statistically significant difference with a threshold MMR rate of 15% (p < 0.0001). Among the imatinib-intolerant CML-CP cohort, 14 and 8 patients achieved an MMR and a CMR, respectively. All of the 50 patients were followed for 18 months. After 18 months of dasatinib therapy, 34 out of 50 patients (68.0%; 95% CI = 53.3 to 80.5%) had achieved an MMR and 22 patients (44.0%; 95% CI = 30.0 to 58.8%) had achieved a CMR.

### Prediction of an improved response to dasatinib at 12 or 18 months based on the efficacy of the molecular response at 1 or 3 months after the initiation of dasatinib treatment (Fig. 2)

To investigate the relationships between response and outcome, the 50 patients were divided into four groups according to the therapeutic effect of dasatinib (Table 2): Group A exhibited more than 10% BCR/ABL mRNA, Group B exhibited 1%-10% BCR/ABL mRNA, Group C exhibited 0.1%-1% BCR/ABL mRNA, and Group D exhibited less than 0.1% BCR/ABL mRNA. At baseline, Group A was composed of 16 patients, Group B was composed of 13 patients, Group C was composed of 21 patients, and Group D did not contain any patients. After one month of dasatinib treatment, Group A was composed of 9 patients, Group B was composed of 4 patients, Group C was composed of 15 patients, and Group D did not contain any patients. After one month of dasatinib treatment, Group A was composed of 9 patients, Group B was composed of 10 patients, Group C was composed of 18 patients, and Group D was composed of 11 patients (Table 3). Three months after dasatinib treatment, Group A was composed of 4 patients, Group B was composed of 4 patients, Group C was composed of 15 patients, and Group D was composed of 21 patients (Table 4). Figure 2 shows the rates of MMR and CMR achievement at both 12 and 18 months. As shown in Fig. 2 and Table 3, the efficacy of the molecular response at 1 month

---

**Table 1. Patient characteristics**

<table>
<thead>
<tr>
<th>Clinical feature</th>
<th>Total</th>
<th>Imatinib-resistant</th>
<th>Imatinib-intolerant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration number</td>
<td>61 (50)*</td>
<td>36 (31)*</td>
<td>25 (19)*</td>
</tr>
<tr>
<td>Median age, year (range)</td>
<td>57 (16-91)</td>
<td>57 (16-74)</td>
<td>57 (24-91)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>41</td>
<td>24</td>
<td>17</td>
</tr>
<tr>
<td>Female</td>
<td>20</td>
<td>12</td>
<td>8</td>
</tr>
</tbody>
</table>

*, Data is for the final analyzed cohort.
after the initiation of dasatinib treatment was capable of predicting a significantly improved response consisting of the achievement of an MMR at 12 months (p < 0.003) or at 18 months (p < 0.003) and the achievement of a CMR at 18 months (p < 0.027). The efficacy of the molecular response at 3 months after the initiation of dasatinib treatment was also capable of predicting an improved response consisting of the achievement of an MMR at 12 months (p < 0.001) or an MMR at 18 months (p < 0.001) and the achievement of a CMR at 12 months (p < 0.002) or a CMR at 18 months (p < 0.001) (Table 4).

Table 2. Number of patients at baseline and responses of patients to dasatinib after 12 and 18 months of treatment

<table>
<thead>
<tr>
<th>Group</th>
<th>Ratio of copy number of BCR/ABL mRNA to ABL mRNA at baseline</th>
<th>Percentage of patients who obtained an MMR, %*</th>
<th>Percentage of patients who obtained a CMR, %**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>At 12 months</td>
<td>At 18 months</td>
<td>At 12 months</td>
</tr>
<tr>
<td>A</td>
<td>10% or more</td>
<td>43.8 (7/16)</td>
<td>50 (8/16)</td>
</tr>
<tr>
<td>B</td>
<td>1-10%</td>
<td>92.3 (12/13)</td>
<td>92.3 (12/13)</td>
</tr>
<tr>
<td>C</td>
<td>0.1-1%</td>
<td>76.2 (16/21)</td>
<td>85.7 (18/21)</td>
</tr>
<tr>
<td>D</td>
<td>0.1% or less (MMR)</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

*, number of patients who obtained an MMR/number of patients at baseline; **, number of patients who obtained an CMR/number of patients at baseline; CMR, complete molecular remission; MMR, major molecular remission; NE, not evaluable

Table 3. Major molecular remission and complete molecular remission achievement rates in four groups at one month after the start of dasatinib therapy

<table>
<thead>
<tr>
<th>Group</th>
<th>Ratio of the copy number of BCR/ABL mRNA for ABL mRNA at 1 month after the start of dasatinib</th>
<th>Percentage of patients who obtained an MMR %*</th>
<th>Percentage of patients who obtained a CMR %**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>At 12 months</td>
<td>At 18 months</td>
<td>At 12 months</td>
</tr>
<tr>
<td>A</td>
<td>10% or more</td>
<td>22.2 (2/9)</td>
<td>22.2 (2/9)</td>
</tr>
<tr>
<td>B</td>
<td>1-10%</td>
<td>80 (8/10)</td>
<td>80 (8/10)</td>
</tr>
<tr>
<td>C</td>
<td>0.1-1%</td>
<td>77.8 (14/18)</td>
<td>77.8 (14/18)</td>
</tr>
<tr>
<td>D</td>
<td>0.1% or less (MMR)</td>
<td>100 (11/11)</td>
<td>100 (11/11)</td>
</tr>
</tbody>
</table>

*, number of patients who obtained an MMR/number of patients at baseline; **, number of patients who obtained an CMR/number of patients at baseline; CMR, complete molecular remission; MMR, major molecular remission; NE, not evaluable

Table 4. Major molecular remission or complete molecular remission achievement rates in four groups at three months after the start of dasatinib therapy

<table>
<thead>
<tr>
<th>Group</th>
<th>Ratio of copy number of BCR/ABL mRNA to ABL mRNA at 3 months after the start of dasatinib</th>
<th>Percentage of patients who obtained an MMR, %*</th>
<th>Percentage of patients who obtained a CMR, %**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>At 12 months</td>
<td>At 18 months</td>
<td>At 12 months</td>
</tr>
<tr>
<td>A</td>
<td>10% or more</td>
<td>0 (0/4)</td>
<td>0 (0/4)</td>
</tr>
<tr>
<td>B</td>
<td>1-10%</td>
<td>25 (1/4)</td>
<td>50 (2/4)</td>
</tr>
<tr>
<td>C</td>
<td>0.1-1%</td>
<td>66.7 (10/15)</td>
<td>73.3 (11/15)</td>
</tr>
<tr>
<td>D</td>
<td>0.1% or less (MMR)</td>
<td>100 (21/21)</td>
<td>100 (21/21)</td>
</tr>
</tbody>
</table>

*, number of patients who obtained an MMR/number of patients at baseline; **, number of patients who obtained an CMR/number of patients at baseline; CMR, complete molecular remission; MMR, major molecular remission; NE, not evaluable

Response according to BCR-ABL mutation status

Eight types of BCR-ABL mutation were detected at baseline in 6 (12%) of the 50 CML-CP patients. Double mutations were detected in two patients (No. 11: M244V and Q252H, and No. 47: P359V and F359I). Four patients (No. 24: A397P, No. 36: E459K, No. 47: P359V and F359I, and No. 62: M351T) had achieved a CMR at 12 months. One of the double-positive patients (No. 11) was unable to achieve an MMR or a CCyR, whereas the other double-positive patient (No. 47) was able to achieve a CMR at 12 months, as described above. Patient No. 15, who had an H396R mutation, was unable to achieve an MMR or a CCyR. A T315I
mutation was identified in two patients (No. 25 & 42) at three months. Both patients achieved a CCyR at 12 months, since hematopoietic stem cell transplantation was performed in both patients. A total of 14 different BCR-ABL mutations affecting 12 different amino acids were detected.

**Safety**

Dasatinib was generally well tolerated, with 3 patients (5%) having to discontinue treatment as a result of adverse hematological events (thrombocytopenia, anemia, neutropenia) at the 12-month follow-up.

Grade 1-2 cytopenia was a common hematologic adverse event, but was generally reversible and was effectively managed using dose adjustments (reductions or temporary interruptions). Six patients with grade 3-4 thrombocytopenia and three patients with grade 3-4 anemia were observed. However, no packed cells or platelet transfusions were administered in the present cohort.

Non-hematologic events that were considered by the investigator to be related to dasatinib therapy were generally mild to moderate in intensity (grade 1 or 2); grade 3 to 4 aspartate aminotransferase elevation was observed in 2 patients (4%), and 1 patient (2%) experienced grade 3 to 4 alanine transaminase elevation.

**DISCUSSION**

This clinical trial examined imatinib-resistant and imatinib-intolerant patients with CML-CP who were treated with dasatinib, a second-generation BCR-ABL inhibitor.

Imatinib, the first BCR-ABL TKI approved for the treatment of Ph-positive CML and Ph-positive acute lymphocytic leukemia, has been shown to be clinically effective. However, resistance develops in some patients, and treatment options for patients who are resistant or intolerant to imatinib have been very limited. Dasatinib is a more potent inhibitor of the BCR-ABL protein tyrosine kinase.
In a recent single-institution study of 119 imatinib-resistant patients receiving dasatinib, nilotinib, or bosutinib as a second-line therapy for CML-CP, Milojkovic et al.25 found that patients achieving a BCR-ABL ≤ 10% at 3 months had significantly improved rates of progression-free survival, overall survival, CCyR, MMR, and CMR. Shah et al.26 supported the value of early molecular and cytogenetic responses in predicting the outcome of patients treated with second-line dasatinib therapy after imatinib failure.

Dasatinib (100 mg) administered once daily appears to offer a favorable long-term risk-benefit profile in patients with imatinib-resistant or imatinib-intolerant CML-CP. The present findings indicate that a consistent subgroup of CML-CP patients who were resistant or intolerant to imatinib were able to obtain a molecular benefit from dasatinib therapy. We previously showed that a BCR-ABL level had a significantly negative correlation with a relative increase in lymphocyte count at 1 and 3 months.21 Here, we were able to show that molecular and cytogenetic responses at 1 and 3 months were highly predictive of the outcomes at 12 and 18 months, and that the achievement of a BCR-ABL ≤ 0.1% (MMR) at 3 months was a particularly strong predictor. A lower level of BCR-ABL transcript at 1 or 3 months was more strongly correlated with the BCR-ABL transcript level at 12 and 18 months (p < 0.001) than a higher level of BCR-ABL. In particular, those with faster and deeper responses to dasatinib (BCR-ABL ≤ 10% at 1 month and BCR-ABL ≤ 1% at 3 months) were more likely to have a significantly improved MMR, and those with a BCR-ABL level of ≤ 1% at 3 months were significantly more likely to have a CMR at 12 or 18 months (p < 0.001 or p < 0.001).

These results are consistent with the findings reported by Hanfstein et al.,27 showing that a group with a 1% IS at 3 months had the best CCyR and MMR, compared with a group with a 1%–10% IS or a group with a 10% IS. Hanfstein et al. proposed that a cut-off of a 1% IS at 3 months seemed to be the best response-predictive surrogate, regardless of the treatment line (i.e., 1st line or 2nd/3rd line) and TKI drug (i.e., imatinib vs. dasatinib vs. nilotinib). Since the transcriptional level of BCR-ABL had a significantly negative correlation with the relative increase in lymphocyte count at 1 and 3 months,21 we speculated that the increase in the number of lymphocytes due to dasatinib therapy would be associated with improved responses to dasatinib, and that the lymphocytes themselves could inhibit the proliferation of leukemic cells through an immune-mediated effect. We here surmised that dasatinib may have a synergistic effect of direct TKI and anti-leukemic immunity.

The results of the present study show a high level of clinical activity for dasatinib in Japanese patients with CML. The rates of MMR and CMR were higher than overseas data.29 Overall, imatinib resistance or intolerance and the baseline BCR-ABL mutation status did not appear to have an impact on the response to dasatinib for CML-CP.29

The most common drug-related adverse events were hematological suppression. Although there were side effects, such as rash, headache, nausea, vomiting, and pyrexia, grade 3 or 4 events were uncommon. The reduction or discontinuation of dasatinib prevented the appearance of grade 3 or 4 peripheral edema or pleural effusion when grade 1 or 2 side effects appeared. Although neutropenia and thrombocytopenia occurred in 43% and 49% of the patients, respectively, these events were generally manageable with dose discontinuation and/or reduction. In the present study, none of the patients required occasional support with hematopoietic growth factors or transfusions. Grade 3 or 4 hemorrhage from the gastrointestinal tract was not reported. The majority of serum biochemistry abnormalities that were observed were mild to moderate in severity. Although imatinib intolerance was present in 38% (19/50) of the CML-CP patients, none of the patients experienced serious side effects or any side effects that led to the discontinuation of dasatinib administration.

In conclusion, although the number of Japanese patients that could be analyzed was relatively small, dasatinib exhibited a favorable long-term risk-benefit profile in patients with imatinib-resistant or imatinib-intolerant CML-CP. The present study is the first to show that a molecular response at 1 month was a strong predictor of outcome among patients with imatinib-resistant or imatinib-intolerant CML-CP.

ACKNOWLEDGEMENTS

This study was supported by the Epidemiological and Clinical Research Information Network (ECRIN). We thank Yumi Miyashita at ECRIN for collecting the data, and Yoshinori Yamamoto at BML for measuring the data.

REFERENCES